Lingang Group accelerates the cultivation of biopharmaceuticals: Leveraging a "fund + base" model to drive a fund size of 170 billion yuan.

At the recent Bio-pharmaceutical Industry Matchmaking Meeting of Lingang Group and the 2025 Lingchuang Blue Bay Fund LP Annual Meeting, Gong Wei, Vice President of Lingang Group, stated that based on the key node of the "14th Five-Year Plan", the group is transitioning from being a "space provider" to a "ecosystem builder". In response to the characteristics of the biopharmaceutical industry, the group is leveraging a fund of 170 billion yuan through the "fund + base" model, and constructing a "relay-style" fund acceleration system. In the future, Lingang Group will continue to focus on scientific and technological resources, industrial resources, and financial resources, supporting the Lingchuang Blue Bay Fund to focus on core tracks with the highest quality park resources, cutting-edge industry scenes, and the richest ecological network, opening up broader application scenarios and ecological resources for fund investment projects, and providing the strongest support for future investment layouts.